End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.18 CNY | +1.70% | +7.33% | -10.55% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.55% | 555M | - | ||
+38.51% | 727B | C+ | ||
+33.05% | 599B | B | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+1.35% | 277B | C+ | ||
+16.00% | 243B | B+ | ||
+8.09% | 205B | B- | ||
-5.77% | 203B | A+ | ||
+6.19% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 003020 Stock
- Ratings Hefei Lifeon Pharmaceutical Co., Ltd.